Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott’s Xience Stent Launch Drives Sales, Stock Gains In Third Quarter

This article was originally published in The Gray Sheet

Executive Summary

Abbott's Xience has become the leading drug-eluting coronary stent in the U.S. since its debut July 2, controlling a market share percentage in the "mid-to-upper 20s," according to the company
Advertisement

Related Content

J&J Orthopedic, Surgical Sales Help Offset 12% Cordis Decline In 2008
J&J Orthopedic, Surgical Sales Help Offset 12% Cordis Decline In 2008
Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling
Medtronic InFuse Sales Flat In Q2; Firm’s Spine Business Still Struggling
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Advertisement
UsernamePublicRestriction

Register

MT026683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel